Table 6.

Adjusted incidence rates of severe complications of urinary tract infection, by sex

	CPRD		HIRD		Medicare
	Dapagliflozin	Comparator GLD	Dapagliflozin	Comparator GLD	Dapagliflozin	Comparator GLD
Females
Treatment episodes, n	4764	17,901	9413	111,587	10,653	163,262
sUTI events, n	7	20	32	418	39	865
Person-years	5361	14,424	5918	55,063	5986	91,689
Adjusted incidence rate (95% CI) per 1000 person-years	1.31 (0.52–2.69)	1.88 (0.82–3.37)	5.41 (3.70–7.63)	7.11 (6.39–7.88)	6.52 (4.63–8.91)	8.70 (8.01–9.42)
Males
Treatment episodes, n	6411	23,768	11,550	132,196	10,744	164,580
sUTI events, n	5	20	15	215	29	555
Person-years	7926	21,490	8091	71,400	6577	101,498
Adjusted incidence rate (95% CI) per 1000 person-years	0.63 (0.20–1.47)	1.04 (0.44–1.88)	1.85 (1.04–3.06)	2.93 (2.52–3.39)	4.41 (2.95–6.33)	5.46 (4.92–6.04)

CI confidence interval; CPRD Clinical Practice Research Datalink, GLD glucose-lowering drug, HIRD HealthCore Integrated Research Database, sUTI severe complications of urinary tract infection

Incidence rates were standardized across the propensity score strata within each exposure group. Then, for each exposure group, the stratum-specific incidence rate was calculated and standardized using the person-years in the dapagliflozin cohort to estimate the standardized incidence rate and variance